RCS - Creo Medical Group - Chris Hancock elected as a Fellow of Royal Academy

Creo MedicalAnnouncement

22/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220922:nRSV2131Aa&default-theme=true

RNS Number : 2131A  Creo Medical Group PLC  22 September 2022

 

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

Chris Hancock elected as a Fellow of Royal Academy of Engineering

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of surgical endoscopy, announces that its Founder and Chief
Technology Officer, Professor Chris Hancock, has been elected as a Fellow of
the Royal Academy of Engineering (RAEng).

 

The Royal Academy of Engineering has elected 72 leading figures in the field
of engineering and technology to its Fellowship. The group comprises 60
Fellows, seven International Fellows and five Honorary Fellows, each of whom
has made exceptional contributions to their own sector, pioneering new
innovations, leading progress in business or academia, providing high level
advice to government, or promoting wider understanding of engineering and
technology.

 

Chris has over 25 years of experience in medical device development. He holds
a personal Chair in the Medical Microwave Systems Research Group at Bangor
University, where he developed a new course in microwave engineering applied
to medicine, and has supervised and mentored a number of students that have
 gone on to become key members of the Creo Medical engineering team (many
have gained higher degrees under his supervision). He is a Fellow of the
Institute of Physics, a Chartered Physicist, Fellow of the Institute of
Engineering and Technology, a Chartered Engineer and a Senior Member of the
IEEE. He also became a Fellow of the Learned Society of Wales in 2022. Chris
is a named inventor and lead author on over 1200 patents/patent applications
and journal publications, and in 2019 was named in the Sunday Times' Maserati
100 annual list of inspiring entrepreneurs, and awarded the Institute of
Physics Katherine Burr Blodgett Gold Medal and Prize for his work in
electrosurgery.

 

Chris was also appointed as a Royal Academy of Engineering Visiting Professor
at UCL in July 2019, and has since given presentations/lectures on how
engineering and medicine can be brought together to develop products that
produce better clinical outcomes for patients all over the world. He also
mentored a number of undergraduate and postgraduate students interested in
developing start-up businesses.

 

The new Fellows will be formally admitted to the Academy at a special ceremony
in London on 8 November, when each Fellow will sign the roll book. In joining
the Fellowship, they will add their unique capabilities to the Academy's
mission to harness the power of engineering to create a sustainable society
and an inclusive economy for all.

 

Chris Hancock, Chief Technology Officer and Founder of Creo Medical,
said: "It is a great honour to be elected to the Fellowship of the Royal
Academy of Engineering, and to join a group of individuals who have
contributed so much to the field.  I am truly humbled and incredibly grateful
for the acknowledgement and support I have received from my peers."

 

Sir Jim McDonald FREng FRSE, President of the Royal Academy of Engineering,
said: "I am delighted to welcome such an array of enormously talented people
to the Fellowship of the Royal Academy of Engineering. From industry and
enterprise to education and government - both national and international -
these are some of our most pioneering and distinguished engineers and
technologists.

 

"In an uncertain world, one thing is certain - engineering skills, vision and
leadership will play a crucial part in addressing the escalating domestic and
global challenges that we face today. The combined connectivity,
professionalism, experience and wisdom of the new Fellows who join us today
will greatly enrich the expertise and support we can provide to the government
and to society in general."

 

Enquiries:

 

 Creo Medical Group plc                             www.creomedical.com (http://www.creomedical.com)
 Richard Rees (CFO)                                 +44 (0)1291 606 005

 Cenkos Securities plc                              +44 (0)20 7397 8900
 Stephen Keys / Camilla Hume (NOMAD)
 Michael Johnson / Russell Kerr (Joint Broker)

 Numis Securities Limited (Joint Broker)            +44 (0)20 7260 1000
 Freddie Barnfield / James Black / Duncan Monteith

 Walbrook PR Ltd                                    Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
 Paul McManus / Sam Allen / Phillip Marriage        Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 / +44 (0)7867 984 082

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions.  CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website: www.creomedical.com
(http://www.creomedical.com)

 

 

About the Royal Academy of Engineering

 

We are a charity delivering public benefit, a National Academy providing
progressive leadership, and a Fellowship bringing together an unrivalled
community of leaders from every part of engineering and technology.

 

HRH The Prince Philip, Duke of Edinburgh was our Senior Fellow, and
instrumental in founding the Academy. HRH The Princess Royal and HRH The Duke
of Kent are Royal Fellows.

 

For more information, please refer to the website: https://raeng.org.uk/
(https://raeng.org.uk/)

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAPPUQWBUPPGQG